Automated Compounding Device (Oncology) Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Gravimetric Compounding System, Volumetric Compounding System), By End User (Hospitals, Chemotherapy Centers, Others), By Region & Competition, 2021-2031F

May 2026 | 192 pages | ID: AC2AC710387CEN
TechSci Research

Abstracts

The Global Automated Compounding Device (Oncology) Market is projected to expand from USD 338.26 Million in 2025 to USD 541.87 Million by 2031, achieving a compound annual growth rate of 8.17%. These specialized robotic systems are engineered to prepare hazardous chemotherapy medications with high precision, thereby minimizing human contact with toxic substances. The market's growth is primarily fueled by the critical necessity to improve medication safety by mitigating compounding errors and the rising global prevalence of cancer, which requires increased volumes of chemotherapy preparations. As reported by the American Society of Health-System Pharmacists in 2024, technologies assisting in sterile product preparation were employed in 62.8% of hospitals, highlighting the growing reliance on automation to ensure accuracy and compliance in handling hazardous drugs.

Despite the evident safety advantages, the market's expansion encounters a major obstacle due to the significant capital investment needed for these sophisticated systems. The high upfront costs of acquisition and implementation, along with the ongoing expenses for maintenance and staff training, frequently discourage smaller healthcare facilities from adopting this technology. Consequently, budgetary constraints persist as a primary barrier that prevents widespread deployment across all levels of healthcare providers.

Market Driver

The escalating global prevalence of cancer and the resulting surge in demand for chemotherapy act as the main catalysts for the adoption of automated compounding devices in oncology. As patient numbers rise, hospital pharmacies face increasing pressure to generate sterile chemotherapy preparations at a scale that manual processes cannot sustainably support. Automation resolves this volume challenge by drastically boosting throughput while upholding the strict sterility standards necessary for immunocompromised patients. This urgency is underscored by the growing disease burden; the American Cancer Society's 'Cancer Facts & Figures 2025' report from January 2025 projected that over 2,041,000 new cancer cases would be diagnosed in the United States that year, indicating a critical trajectory where manual compounding methods will fail to meet expanding clinical needs.

Concurrently, a stronger emphasis on occupational safety and exposure reduction is driving healthcare facilities to transition toward robotic systems. Handling hazardous antineoplastic drugs presents severe health risks to pharmacy staff, including potential mutagenic and carcinogenic effects from prolonged exposure. Regulatory bodies are reacting with stricter guidelines that require containment strategies, which are often best realized through automation. According to the National Institute for Occupational Safety and Health's December 2024 'List of Hazardous Drugs in Healthcare Settings, 2024', 25 new drugs were added to the hazardous category, reinforcing the broadening scope of substances requiring strict containment. This shift toward technology is further evidenced by wider industry trends; an article in Pharmacy Times from September 2025 titled 'Intelligent Pharmacy' noted that nearly 50% of global healthcare organizations intended to incorporate AI-driven automation into their workflows by the end of the year.

Market Challenge

The considerable capital investment necessary for automated compounding devices serves as a major restraint on market expansion, specifically for smaller healthcare institutions. Procurement entails not only the high purchase price of the robotic systems but also extensive costs related to facility modifications, software integration, and specialized personnel training. These financial demands create a barrier for community hospitals and rural centers operating on restricted budgets, preventing them from transitioning away from manual chemotherapy preparation. As a result, the market remains heavily concentrated within large academic research centers, limiting broader commercial penetration.

This economic obstacle is evident in adoption metrics across major healthcare regions. As stated by the European Association of Hospital Pharmacists in 2024, fewer than 30% of hospital pharmacies in Europe had fully or partially adopted automation technologies. This statistic demonstrates that, despite the critical need for safety in oncology compounding, the financial burden of these technologies stifles widespread implementation. Consequently, the market struggles to capture volume in lower-tier segments, directly hampering the overall growth of the industry.

Market Trends

The transition toward gravimetric verification technologies marks a fundamental evolution in safety, moving beyond visual volumetric methods. This trend is gaining traction as facilities recognize that weight-based verification provides a precise method to ensure the concentration of oncology ingredients. Scale-based checks detect deviations that manual methods miss, significantly mitigating dosing errors. However, adoption remains early due to operational complexity; according to the 'Is IVWMS Adoption Rate Fast Enough?' article in Pharmacy Practice News from December 2024, gravimetrics to verify dose, amount, and volume was utilized by only 7.7% of hospital pharmacies overall in 2023.

Additionally, the rise of personalized medicine and genomic-based dosing is reshaping the market by demanding higher precision for patient-specific chemotherapy. Treatments now rely on biomarker-driven therapies requiring exact dosages tailored to an individual’s genetic profile, necessitating the accuracy that only robotic systems can consistently deliver. This forces compounding devices to adapt to complex batch sizes and handle high-value biologics with zero waste. This trajectory is highlighted by regulatory trends; according to the Personalized Medicine Coalition's May 2025 report, 'Personalized Medicine at FDA: The Scope & Significance of Progress in 2024,' the FDA approved 18 new personalized medicines in 2024, representing 38% of newly approved therapeutic molecular entities.

Key Market Players

• Baxter International Inc.
• B. Braun SE.
• COMECER S.p.A.
• ARxIUM Inc.
• Omnicell Inc.
• Grifols, S.A.
• Weibond Technology
• Equashield LLC.
• ICU Medical, Inc
• NewIcon Oy

Report Scope

In this report, the Global Automated Compounding Device (Oncology) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Automated Compounding Device (Oncology) Market, By Technology
• Gravimetric Compounding System
• Volumetric Compounding System
• Automated Compounding Device (Oncology) Market, By End User
• Hospitals
• Chemotherapy Centers
• Others
• Automated Compounding Device (Oncology) Market, By Region
• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Automated Compounding Device (Oncology) Market.

Available Customizations:

Global Automated Compounding Device (Oncology) Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL AUTOMATED COMPOUNDING DEVICE (ONCOLOGY) MARKET OUTLOOK

5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Technology (Gravimetric Compounding System, Volumetric Compounding System)
  5.2.2. By End User (Hospitals, Chemotherapy Centers, Others)
  5.2.3. By Region
  5.2.4. By Company (2025)
5.3. Market Map

6. NORTH AMERICA AUTOMATED COMPOUNDING DEVICE (ONCOLOGY) MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Technology
  6.2.2. By End User
  6.2.3. By Country
6.3. North America: Country Analysis
  6.3.1. United States Automated Compounding Device (Oncology) Market Outlook
    6.3.1.1. Market Size & Forecast
      6.3.1.1.1. By Value
    6.3.1.2. Market Share & Forecast
      6.3.1.2.1. By Technology
      6.3.1.2.2. By End User
  6.3.2. Canada Automated Compounding Device (Oncology) Market Outlook
    6.3.2.1. Market Size & Forecast
      6.3.2.1.1. By Value
    6.3.2.2. Market Share & Forecast
      6.3.2.2.1. By Technology
      6.3.2.2.2. By End User
  6.3.3. Mexico Automated Compounding Device (Oncology) Market Outlook
    6.3.3.1. Market Size & Forecast
      6.3.3.1.1. By Value
    6.3.3.2. Market Share & Forecast
      6.3.3.2.1. By Technology
      6.3.3.2.2. By End User

7. EUROPE AUTOMATED COMPOUNDING DEVICE (ONCOLOGY) MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Technology
  7.2.2. By End User
  7.2.3. By Country
7.3. Europe: Country Analysis
  7.3.1. Germany Automated Compounding Device (Oncology) Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Technology
      7.3.1.2.2. By End User
  7.3.2. France Automated Compounding Device (Oncology) Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Technology
      7.3.2.2.2. By End User
  7.3.3. United Kingdom Automated Compounding Device (Oncology) Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Technology
      7.3.3.2.2. By End User
  7.3.4. Italy Automated Compounding Device (Oncology) Market Outlook
    7.3.4.1. Market Size & Forecast
      7.3.4.1.1. By Value
    7.3.4.2. Market Share & Forecast
      7.3.4.2.1. By Technology
      7.3.4.2.2. By End User
  7.3.5. Spain Automated Compounding Device (Oncology) Market Outlook
    7.3.5.1. Market Size & Forecast
      7.3.5.1.1. By Value
    7.3.5.2. Market Share & Forecast
      7.3.5.2.1. By Technology
      7.3.5.2.2. By End User

8. ASIA PACIFIC AUTOMATED COMPOUNDING DEVICE (ONCOLOGY) MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Technology
  8.2.2. By End User
  8.2.3. By Country
8.3. Asia Pacific: Country Analysis
  8.3.1. China Automated Compounding Device (Oncology) Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Technology
      8.3.1.2.2. By End User
  8.3.2. India Automated Compounding Device (Oncology) Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Technology
      8.3.2.2.2. By End User
  8.3.3. Japan Automated Compounding Device (Oncology) Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Technology
      8.3.3.2.2. By End User
  8.3.4. South Korea Automated Compounding Device (Oncology) Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Technology
      8.3.4.2.2. By End User
  8.3.5. Australia Automated Compounding Device (Oncology) Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Technology
      8.3.5.2.2. By End User

9. MIDDLE EAST & AFRICA AUTOMATED COMPOUNDING DEVICE (ONCOLOGY) MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Technology
  9.2.2. By End User
  9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
  9.3.1. Saudi Arabia Automated Compounding Device (Oncology) Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Technology
      9.3.1.2.2. By End User
  9.3.2. UAE Automated Compounding Device (Oncology) Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Technology
      9.3.2.2.2. By End User
  9.3.3. South Africa Automated Compounding Device (Oncology) Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Technology
      9.3.3.2.2. By End User

10. SOUTH AMERICA AUTOMATED COMPOUNDING DEVICE (ONCOLOGY) MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Technology
  10.2.2. By End User
  10.2.3. By Country
10.3. South America: Country Analysis
  10.3.1. Brazil Automated Compounding Device (Oncology) Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Technology
      10.3.1.2.2. By End User
  10.3.2. Colombia Automated Compounding Device (Oncology) Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Technology
      10.3.2.2.2. By End User
  10.3.3. Argentina Automated Compounding Device (Oncology) Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Technology
      10.3.3.2.2. By End User

11. MARKET DYNAMICS

11.1. Drivers
11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. GLOBAL AUTOMATED COMPOUNDING DEVICE (ONCOLOGY) MARKET: SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. COMPETITIVE LANDSCAPE

15.1. Baxter International Inc.
  15.1.1. Business Overview
  15.1.2. Products & Services
  15.1.3. Recent Developments
  15.1.4. Key Personnel
  15.1.5. SWOT Analysis
15.2. B. Braun SE.
15.3. COMECER S.p.A.
15.4. ARxIUM Inc.
15.5. Omnicell Inc.
15.6. Grifols, S.A.
15.7. Weibond Technology
15.8. Equashield LLC.
15.9. ICU Medical, Inc
15.10. NewIcon Oy

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER